CCL2 expression and its correlation with CCL4/CCR5/ NF-κB pathway in patients with periodontal disease by Zhang L et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 United States 
License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Zhang L, Wang Y, Wang H, Huang Q, Yu M, Bao G, Li C, Deng J, Cui Z, Cao D.  
CCL2 expression and its correlation with CCL4/CCR5/ NF-κB pathway in 
patients with periodontal disease.  
International Journal of Clinical and Experimental Pathology  
2017, 10(4), 4400-4410. 
 
Copyright: 
© e-Century Publishing Corporation. Published under  the “Creative Commons Attribution Non- 
Commercial License”, enabling the unrestricted non-commercial use, distribution, and reproduction of 
the published article in any medium, provided that the original work is properly cited. 
Link to journal website: 
http://www.ijcep.com/V10_No4.html  
Date deposited:   
02/06/2017 
 
Int J Clin Exp Pathol 2017;10(4):4400-4410
www.ijcep.com /ISSN:1936-2625/IJCEP0050704
Original Article
CCL2 expression and its correlation with CCL4/CCR5/
NF-кB pathway in patients with periodontal disease
Lin Zhang1, Yonglan Wang1, Hong Wang2, Qing Huang3, Min Yu4, Gang Bao1, Changyi Li1, Jiayin Deng1, 
Zhuang Cui5, Deqing Cao5
1School of Dentistry, Hospital of Stomatology, Tianjin Medical University, Tianjin, China; 2Institute of Biomedi-
cal Engineering, Academy of Medical Science & Peking Union Medical College, Tianjin, China; 3Department of 
Periodontics, Tianjin Stomatological Hospital, Tianjin, China; 4Institute of Genetic Medicine, Newcastle University, 
Newcastle Upon Tyne, United Kingdom; 5School of Public Health, Tianjin Medical University, Tianjin, China
Received February 13, 2017; Accepted February 25, 2017; Epub April 1, 2017; Published April 15, 2017
Abstract: Periodontal disease (PD) is characterized by continuous leukocyte infiltration. CCL2 plays an important 
role in periodontal pathogenesis. In this study, we studied the possibility of a pathway involved in the production of 
CCL2 in peripheral blood (PB) and gingival tissues of chronic periodontitis (CP) and aggressive periodontitis (AgP) 
patients based on our previous work about chemokine signaling pathway leading to production of CCL2 in rheuma-
toid arthritis (RA) patients. Total RNA was isolated from PB leukocytes and gingival tissue in periodontitis patients 
and healthy controls. Real-time PCR was used to determine CCL4, CCR5, NF-кB, and CCL2 expression. Serum level 
of CCL2 was assessed by enzyme-linked immunosorbent assay. The production of CCL2 in gingival tissue was 
analyzed by immunohistochemistry. The expression of CCL2 mRNA in CP and AgP patients was greatly decreased 
than those in healthy controls, both in gingival tissue and on PB leukocyte. The mRNA expression levels of CCL4, 
CCR5 and NF-кB in the patients with different periodontal diseases were higher than those in the Healthy group. 
However, in spite of the higher expression of NF-кB on AgP PB leukocytes, and more intense CCR5 expression in the 
CP gingival tissue, the differences were not statistically significant. Serum CCL2 levels were elevated in both CP and 
AgP patients. Histological examination of CP patients revealed extensive CCL2 expression in mild inflamed gingival 
tissue. These data provide evidence that the CCL4/CCR5/NF-кB pathway may be involved in CCL2 expression on 
PB leukocytes of clinically CP patients.
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Introduction
Periodontal diseases are chronic inflammatory 
diseases of the attachment structures of the 
teeth. They are triggered by periodontopatho-
gens and the clinical outcome is highly influ-
enced by the host local immune response [1]. 
The inflammatory reaction is a key step in the 
development of the immune response, and the 
immune protection depends on the nature of 
the migrating cells. Infiltration of mononuclear 
cells is a common feature of many forms of 
chronic inflammation including periodontitis 
[2]. In this situation, chemokines are thought to 
play important roles in the immunopathogene-
sis of periodontal diseases. The altered chemo-
tactic behavior was observed in patients with 
periodontitis [3].
Monocyte chemoattractant protein-1 (CCL2) 
and macrophage inflammatory protein-1β 
(CCL4) are well defined CC chemokines. High 
levels of CCL2 have been reported in the gingi-
val crevicular fluid of patients with both chronic 
periodontitis (CP) and aggressive periodontitis 
(AgP) [4]. The Monocyte chemoattractant pro-
tein activity of the crevicular fluids of adult peri-
odontal patients increases with an increase in 
severity of this disease, also suggesting that 
CCL2 could be involved in the mechanism of 
monocyte recruitment from the circulating pool 
into periodontal tissues. CCL2 induces chemo-
taxis of circulating monocytes and is different 
from several other chemoattractants in that it 
is relatively specific for monocytes [5]. In addi-
tion, it has been demonstrated that CCL2 is 
synthesized in inflamed gingiva by vascular 
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endothelial cells and mononuclear phagocytes 
[5]. CCL2 has also been implicated in the 
pathogenesis of various systemic diseases, 
such as granulomatous disease, rheumatoid 
arthritis, heart disease, bone trauma and asth-
ma [5]. CCL4 might play an important role in 
the host response by recruiting inflammatory 
cells into the foci of active inflammation and by 
inducing the release of other cell mediators. It 
exhibits a chemotactic characteristic for the 
cluster of differentiation 4 (CD4+) T cells [6] 
and has been shown to be more prevalent in 
diseased periodontal tissues and GCF com-
pared to healthy sites [7]. CCL4 is also specifi-
cally increased in several inflammatory diseas-
es such as rheumatoid arthritis (RA) [8]. CCR5 
has been expressed on monocytes/macro-
phages. CCL4 chemokine is said to be ligand 
for CCR5. The CCR5 expressed on the type 1 
helper T cell has been shown to induce alveolar 
bone loss in a mouse model of experimental 
periodontitis [9]. CCR5 was described as a 
higher periodontal disease severity mediator in 
humans and mice [10], but the mechanisms by 
which CCR5 determines periodontal disease 
outcome remain unknown.
CCL2, CCL4 and CCR5 have been shown to be 
involved in inflammatory immune responses. 
However, the mechanism of interaction of these 
molecules in an inflammatory milieu, which 
helps perpetuate inflammation in periodontitis, 
is not understood; the cellular mechanisms 
mediating CCL2 production are completely 
unknown. Multiple signaling mechanisms have 
been reported to be involved in the intracellular 
activation of CCL2 gene expression in peri-
odontial tissue by a various stimuli [11]. Rh- 
eumatoid Arthritis (RA) and chronic and aggres-
sive periodontitis are chronic inflammatory dis-
orders characterized by deregulation of the 
host inflammatory response. Both diseases 
share risk factors and have pathological path-
ways in common [12]. We previously showed 
that the chemokine signaling pathway (CCL4/
CCR5/c-Jun and c-Fos/CCL2) was involved in 
CCL2 expression in collagen-induced arthritis 
(CIA) rat and RA patient tissues [13, 14]. The 
present study was designed to estimate CCL2, 
CCL4 and CCR5 levels in periodontal health 
and disease as well as to investigate the signal-
ing mechanisms involved in the CCL2 induction 
in different forms of human periodontal 
disease.
Materials and methods
Patients and specimens
A total of 52 individuals were recruited in the 
study. All subjects were recruited from the 
Department of Periodontology, School of 
Dentistry, Tianjin Medical University, Tianjin 
and the Department of Periodontology, Tianjin 
Stomatological Hospital, Tianjin between 2014 
and 2015. Complete medical and dental histo-
ries were taken from all subjects. None of the 
subjects had a history of systemic disease and 
none had received antibiotics or other medi-
cines or periodontal treatment within the past 
4 months. None of the women were pregnant, 
lactating and postmenopausal. The partici-
pants who had never smoked or had quitted 
smoking for at least 6 months were included. 
The diagnosis of periodontitis from the study 
participants were defined in accordance with 
the classification agreed at The American 
Academy of Periodontology in 1999 [15]. In 
brief, the diagnoses, which are generalized 
aggressive periodontitis (GAgP), chronic peri-
odontitis (CP) and healthy groups, were made 
based on the relevant dental history and clini-
cal records. The subjects were classified as 
follows.
CP group 
1) age ≥ 35 years, 2) attachment loss (AL) ≥ 5 
mm on more than one tooth, and 3) more than 
three sites of probing depth (PD) > 6 mm on 
more than one tooth distributed in each quad-
rant, but with no evidence of rapid progre- 
ssion.
GAgP group
1) eight or more teeth with AL ≥ 5 mm, 2) PD > 
6 mm, and 3) at least three affected teeth that 
were not first molars or incisors. 
Healthy group
No evidence of AL and PD at more than one site 
> 3 mm, clinical inflammation, sulcular bleed-
ing and radiographic evidence of bone loss.
Determination of periodontal status
To determine the clinical periodontal status, all 
subjects had a clinical periodontal examination 
including the measurement of probing depth 
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and clinical attachment loss. Attachment level 
and pocket depth measurements were taken at 
6 sites per tooth by a single calibrated investi-
gator. The calibrated examiner performed all 
the clinical assessments using William’s peri-
odontal probe. Measurements were made at 
the mesiobuccal, buccal, distobuccal, distolin-
gual, lingual and mesio-lingual positions. Dic- 
hotomous measurement of supragingival pla- 
que (PI) and bleeding on probing (BOP) were 
also performed at 6 sites per tooth.
Collection of serum samples
Blood samples were obtained from 22 patients 
(n=9 for GAgP group and n=13 for CP group, 
respectively). For eighteen (n=9 for GAgP group 
and n=9 for CP group, respectively) of the twen-
ty-two corresponding paired samples, an addi-
tional set of peripheral blood leukocytes was 
used for analyses of gene expression. Control 
peripheral blood leukocytes and control sera 
were obtained from a group of 9 healthy indi-
viduals who were matched with the GAgP group 
(n=9) and CP group (n=13) for sex and mean 
age. 
Collection of gingival tissues
Gingival tissue was obtained from 21 subjects 
undergoing periodontal surgery for disease and 
nondisease related reasons. Samples of 
inflamed gingival tissues were obtained from 
13 patients with chronic periodontitis. All sub-
jects in this group had previous oral hygiene 
instruction and scaling and root planning prior 
to surgery, but continued to demonstrate bleed-
ing on probing. The control group comprised 8 
periodontally healthy subjects from whom biop-
sies of gingival tissue were taken during surgi-
cal procedures for wisdom teeth removal.
Each specimen was divided into two samples 
which were approximately in similar sizes. One 
sample was stored in liquid nitrogen and used 
for quantitative real-time PCR, whereas the 
other sample was stored in 10% formalin solu-
tion for immunohistochemistry and histopatho-
logical assessment. The experimental protocol 
was approved by the Human Ethics Review 
Committee at our institution, and signed con-
sent was obtained from each patient.
Quantitative real-time polymerase chain reac-
tion (PCR)
Total RNA was isolated from gingival tissue 
using the TRIZOL reagent (10296010; Invitro- 
gen, Carlsbad, CA, USA). The leukocytes were 
prepared from 10 ml of EDTA anticoagulated 
peripheral blood (PB) and were washed with 
phosphate-buffered saline (PBS), then lysed 
with TRIZOL LS reagent. The total cellular RNA 
was purified according to the instruction ma- 
nual. The reverse transcription reaction was 
performed with Superscript III first-strand 
kit (Invitrogen, 18080-051) according to the 
manufacturer’s instructions. Messenger RNA 
(mRNA) expression was determined by real-
time PCR using SYBR Green Master Mix under 
standard thermocycler conditions (4367659; 
Applied Biosystems, Foster City, CA, USA). Data 
were collected and quantitatively analyzed on 
an ABI Prism 7900 Sequence Detection System 
(Applied Biosystems). A human GAPDH gene 
was used as an endogenous control for sample 
normalization. Results were presented as the 
fold expression relative to that of GAPDH. PB 
leukocyte samples (healthy, CP and GAgP) were 
analyzed by one-way analysis of variance 
(ANOVA) with LSD-t test. Student’s t test was 
used to evaluate chemokine/cytokine produc-
tion by gingival tissue between the CP and con-
trol groups. PCR primers were as follows: for 
human GAPDH, forward 5’-ATTGCCCTCAACGA- 
CCACT-3’ and reverse 5’-ATGAGGTCCACCACC- 
CTGT-3’; for human CCL2, forward 5’-CTTCTG- 
TGCCTGCTGCTCAT-3’ and reverse 5’-CGGAG- 
TTTGGGTTTGCTTGTC-3’; for human CCL4, for-
ward 5’-CTGTGCTGATCCCAGTGAATC-3’ and 
reverse 5’-TCAGTTCAGTTCCAGGTCATACA-3’; for 
human CCR5, forward 5’-TTCTGGGCTCCCTAC- 
AACATT-3’ and reverse 5’-TTGGTCCAACCTGTT- 
AGAGCTA-3’, and for human NF-кB, forward 
5’-TCTGGCGCAGAAGTTGGGT-3’ and reverse 
5’-CCAGAGACCTCATAGTTGT-3’.
Enzyme-linked immunosorbent assays (ELI-
SAs) 
Serum level of CCL2 was measured using an 
enzyme-linked immunosorbent assay (ELISA) 
kit (Catalog no. 4338807, BioLegend, Inc., 
USA), according to the manufacturer’s instruc-
tions. The plate was read at 450 nm in an ELISA 
plate reader (Multiskan MK3, Thermo Scientific, 
MA, USA). Concentrations of CCL2 in each sam-
ple were extrapolated from standards. The 
detection limit of the CCL2 assay was 1.6 pg/
ml. The range of detection level for CCL2 was 
from 7.8 to 500 pg/ml. Differences between 
the three study groups (healthy, CP and GAgP) 
were determined with one-way analysis of vari-
ance (ANOVA). When ANOVA showed statistical 
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significance, LSD-t test was performed to 
explore the differences between any two 
groups.
Immunohistochemical analysis 
The paraffin sections were prepared for routine 
histological and immunohistochemical exami-
nation. For immunostaining, all sections were 
treated in a microwave oven four times with 
citrate buffer (pH 6.0) for 5 min at 960 W. 
Sections were incubated overnight at 4°C with 
the primary polyclonal rabbit antibody (LifeSpan 
BioSciences, Inc., Seattle, WA, USA), namely 
anti-CCL2 in dilutions 1:50. Subsequently, sec-
tions were incubated with biotinylated goat 
anti-rabbit IgG (H+L) (Jackson) followed by 
horseradish peroxidase streptavidin (Vector) 
for 1 h at room temperature. Color was devel-
oped using 3,3’-diamino benzidine tetrahydro-
chloride, and sections were counterstained 
with Mayer’s hematoxylin.
Statistical analysis
Comparisons between three groups were per-
formed using one-way ANOVA followed by a 
LSD-t test. Comparisons between 2 groups 
were performed using student’s t tests. All 
experiments were performed at least twice 
with comparable results. Data are presented 
as means ± standard deviation (SD). The signifi-
cance levels were set to P < 0.05. These calcu-
lations were carried out using a statistical 
Software Package Program (SPSS version12.0, 
Software Package Programme, Chicago, Illinois, 
USA).
Results 
CCL2, CCL4, CCR5, and NF-кB genes expres-
sion in gingival tissues and peripheral blood of 
the periodontitis patients
The mRNA levels of CCL2, CCL4, CCR5 and 
NF-кB were determined using real-time PCR. 
The real-time PCR results were converted to 
mRNA, and fold changes were calculated. Our 
data show that CCL4 expression on the leuko-
cytes in CP (1.66-fold, P < 0.05; Figure 1) and 
GAgP PB was higher than in the control group 
PB (Figure 1). CCL4 expression was significant-
ly up-regulated in the gingival tissue of CP 
patients as compared with their expression in 
normal gingival tissue (Figure 1). We also 
detected CCR5 expression was significantly 
increased on leukocytes in both CP and GAgP 
PB compared with its expression in normal PB 
(Figure 1). CCR5 was more intensely expressed 
in CP gingival tissue than in controls, although 
there was absence of statistical significance 
(Figure 2). 
Figure 1. Real-time PCR analysis of CCL2, CCL4, CCR5, and NF-кB mRNA levels on CP and GAgP PB leukocytes. 
The relative mRNA expression levels were normalized to the levels of GAPDH. The significance of differences was 
determined using analysis of variance (ANOVA)/LSD-t test. *,‡P < 0.05, open bars healthy controls (n=9); solid bars 
CP patients (n=9); coarse stippling bars GAgP patients (n=9).
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Our results have also shown that NF-кB is high-
ly expressed both on leukocytes and in the gin-
gival tissue of CP patients (P < 0.05; Figures 1 
and 2). On the other hand, in aggressive peri-
odontitis (AgP) patients the intensity of NF-кB 
mRNA expression on leukocytes was higher 
(Figure 1), in spite of a lack of statistical 
significance.
It is worth noting that the CP gingival tissue 
exhibits significantly lower CCL2 expression 
compared with controls (Figure 2), the CCL2 
was also significantly down-regulated on CP PB 
leukocytes than control leukocytes (Figure 1), 
as determined by quantitative RT-PCR. The rel-
ative mRNA levels of these four genes and fold 
changes on PB leukocytes and in gingival tis-
sue from the real-time PCR are summarized in 
Table 1.
CCL2 levels in serum of CP and GAgP patients
To determine whether PB from both patient 
groups (i.e. generalized aggressive periodonti-
tis and chronic periodontitis) contained signifi-
cant quantities of CCL2 compared to normal 
volunteers, serum CCL2 levels were deter-
mined by ELISA using 13 CP samples and 9 
GAgP samples. Serum levels of CP CCL2 ranged 
from 134.52 pg/ml to 208.31 pg/ml (mean 
173 ± 26 pg/ml). The range of detection level 
for CCL2 in GAgP serum samples was from 
101.31 pg/ml to 185.34 pg/ml (mean 135 ± 
33 pg/ml). In contrast normal sera obtained 
Figure 2. Real-time PCR analysis of CCL2, CCL4, CCR5, and NF-кB mRNA levels in CP gingival tissue. The relative 
mRNA expression levels were normalized to the levels of GAPDH. The significance of differences was determined 
using Student’s t-test. #P < 0.05, open bars healthy controls (n=8); solid bars CP patients (n=13).
Table 1. Summary of CCL2, CCL4, CCR5, NF-кB gene expression in Real-time PCR
Gene 
name
Relative mRNA expression in 
CP gingival tissue (CP/control) Fold
Relative mRNA expression on 
CP PB leukocytes (CP/control) Fold
Relative mRNA expression on 
GAgP PB leukocytes (GAgP/control) Fold
CCL2 (0.59 ± 0.25)/(1.06 ± 0.40) 0.56# (0.15 ± 0.01)/(1.01 ± 0.11) 0.14* (0.29 ± 0.03)/(1.01 ± 0.11) 0.29‡
CCL4 (2.73 ± 0.72)/(1.02 ± 0.20) 2.67# (1.66 ± 0.09)/(1.00 ± 0.09) 1.66* (1.22 ± 0.12)/(1.00 ± 0.09) 1.21‡
CCR5 (1.58 ± 0.47)/(1.10 ± 0.30) 1.44 (1.81 ± 0.36)/(1.01 ± 0.17) 1.78* (2.95 ± 0.28)/(1.01 ± 0.17) 2.90‡
NF-кB (1.88± 0.70)/(0.91±0.11) 2.07# (2.62 ± 0.74)/(1.00 ± 0.09) 2.60* (1.03± 0.09)/(1.00 ± 0.09) 1.03
#Statistically significant difference to the healthy controls (P < 0.05; student’s t-test; n=13). *Statistically significant difference to the healthy 
controls (P < 0.05; one-way ANOVA with LSD-t test; n=9). ‡Statistically significant difference to the healthy controls (P < 0.05; one-way ANOVA with 
LSD-t test; n=9). RT-PCR, real time polymerase chain reaction; mRNA, messenger RNA; CP, chronic periodontitis; GAgP, generalized aggressive 
periodontitis; PB, peripheral blood.
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from 9 volunteers contained significantly less 
CCL2 (54.77 pg/ml to 123.87 pg/ml) (mean 92 
± 28 pg/ml). ANOVA showed that differences in 
the level of CCL2 among these groups were sta-
tistically significant at P < 0.05. Pairwise com-
parisons showed that the differences were sta-
tistically significant between CP and control 
and between GAgP and control groups (Figure 
3). 
Expression of CCL2 in inflamed gingival tissues
Experiments utilizing a polyclonal antibody 
CCL2 were carried out to determine whether 
gingival tissues from CP patients expressed 
CCL2 protein in vivo. The samples were placed 
into 3 groups according to the gingival inflam-
matory cell counts (monocyte + lymphocyte). 
Paraffin sections from normal, mild, and highly 
inflamed gingival tissues were examined by 
incubation with CCL2 antibody. Virtually no 
CCL2+ cells could be detected in an extensive 
inflammatory infiltrate in the gingival tissue 
from a CP patient. Numerous CCL2+ cells sig-
nal increased in minimally inflamed CP gingival 
tissue. Little or no CCL2 expression was shown 
in normal gingival tissue from healthy patients 
showed a low degree of inflammation.
Figure 4 shows adjacent gingival tissue sec-
tions from patients with chronic adult periodon-
titis. Positive cells are predominantly expressed 
along the basal layer of the junctional epitheli-
um and by endothelial cells, fibroblast, and 
mononuclear phagocytes in the inflammatory 
infiltrate (Figure 4F and 4K). Figure 4B, 4C, 4G, 
4H, 4L and 4M show a representative area at 
higher magnification. Slides were negative 
when the primary antibody was omitted (Figure 
4D, 4I and 4N). Histological examination of CP 
gingival tissues demonstrated a significant 
increase in chronic gingival inflammation 
(Figure 4J and 4O). CCL2 staining was either 
faint or nonexistent in severe inflamed gingival 
tissues of patients with chronic adult periodon-
titis (Figure 4K). Figure 4F shows a mild 
inflamed gingival tissue. We detected CCL2-
positive cells in the basal layers of epithelium. 
Endothelial cells found in small blood vessels 
of Figure 4F were clearly positive for CCL2 ex- 
pression. CCL2-expressing monocyte-like cells 
were also found at the inflamed site. Of note is 
the number of immunoreactive CCL2 cells 
decreased with increasing severity of inflam- 
mation. 
Discussion 
Leukocyte migration to the site of inflammation 
plays an important role in the initiation and per-
petuation of periodontial diseases. It is a highly 
complex process involving many signaling path-
ways and molecules/receptors. In the present 
study, we investigated CCL2, CCL4, CCR5 and 
NF-кB levels in gingival tissue and peripheral 
blood (PB) of patients with different periodontal 
diseases.
The mRNA expression levels of CCL4, CCR5 
and NF-кB in patients with different periodontal 
diseases were higher than those in the healthy 
group on real-time PCR analysis. 
The expression of NF-кB (P=0.67) on GAgP PB 
leukocytes and the intensity of CCR5 (P=0.13) 
expression in the CP gingival tissue were some-
what higher in the patients than in controls, but 
failed to reach the level of significance (Figures 
1 and 2), possibly owing to the small numbers 
of patients.
We investigated local and systemic level of 
CCL2 in patients with CP and GAgP periodonti-
tis at both the protein and mRNA levels. In this 
Figure 3. Concentrations of CCL2 protein in serum, 
assessed by ELISA technique. The significance of 
differences was determined using analysis of vari-
ance (ANOVA)/LSD-t test. *Significant difference from 
healthy group. ‡Indicates a significant difference 
between generalized aggressive periodontitis and 
chronic periodontitis group. *,‡P < 0.05, open bars 
healthy controls (n=9); solid bars CP patients (n=13); 
coarse stippling bars GAgP patients (n=9).
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study, serum CCL2 was found to be significant-
ly elevated in chronic and generalized aggres-
sive periodontitis compared with healthy con-
trols (Figure 3). The possible reason for incre- 
ase in serum levels of CCL2 could be either 
spillover from the GCF or gingival tissues to 
peripheral circulation or it could be due to sys-
temic inflammatory response to progressive 
disease in the periodontal pocket.
In order to investigate the CCL2 expression in 
gingival tissue biopsies from CP patients exhib-
iting different degrees of inflammation, we per-
formed immunohistochemistry. Of particular 
interest was the observation that the marked 
CCL2 expression was detected in minimally 
inflamed gingival samples, there is little or no 
CCL2 expression in moderate-to-severe infla- 
med gingival tissue (Figure 4). Moreover, the 
levels of CCL2 correlated inversely with the 
degree of gingival inflammation. This could be 
due to regulatory mechanisms of CCL2 locally. 
These observations strongly suggest that CCL2 
may induce migration of leukocytes in the ear-
lier phases of gingival inflammation, other 
mediators rather than CCL2 plays a significant 
role in the recruitment of monocytes/macro-
phages into the gingival tissues in the later 
stages of inflammatory process. A high degree 
of redundancy was observed in chemokine-
receptor interactions, since many chemokines 
bind to more than one receptor and vice versa 
[16]. These findings corroborate with the con-
cept of the complexity of the chemokine/che-
mokine receptor system. A possible relation-
ship between the amount of CCL2 and severity 
of inflammation has been reported for peri-
odontal disease. It has been previously demon-
strated that only few leukocytes expressed 
CCL2 in the periodontal tissues [2]. In contrast 
to these results, Yu et al. found that CCL2 was 
expressed in gingival tissues of patients with 
mild-to-moderate periodontitis and these lev-
els have been demonstrated to be correlated 
with the degree of inflammation [5]. It is note-
worthy that the expressions of CCL2 mRNA in 
CP and GAgP patients was greatly decreased 
than those in healthy controls, both in gingival 
tissue and on PB leukocyte (Figures 1 and 2). 
The lower CCL2 mRNA concentrations were 
found, possibly due to the short half-life and 
instability of its mRNA.
Next, we investigated the signaling pathways 
involved in the production of CCL2 in different 
forms of human periodontal disease. It is of 
interest to demonstrate which transcriptional 
factor is involved in CCL2 expression. There are 
several binding sites for a number of transcrip-
tion factors, including NF-кB, Sp-1, and AP-1, in 
Figure 4. Immunohistochemical study of CCL2 expression in gingival tissue from CP patients. Photomicrographs 
were taken from healthy controls (A-E), minimally inflamed human gingival tissue from CP patients (F-J), highly in-
flamed human gingival tissue from CP patients (K-O). (A-C, F-H, K-M) Show CCL2 immuoreactivity (brown staining). 
(D, I, N) Show background staining with CCL2 antibody omitted (blue staining). (O) Show maximal inflammatory cell 
infiltration. (Hematoxylin and eosin staining in (E, J, O); avidin-biotin-peroxidase staining in (A-C, F-H, K-M). Original 
magnification × 400 in (A, D-F, I-K, N and O); × 600 in (B, C, G, H, L and M). bar =100 μm.
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the 5’ region of the CCL2 gene [17]. The pres-
ent study determined that significantly higher 
levels of NF-кB mRNAs are found on PB leuko-
cyte (P=0.0007) and in gingival tissue biopsies 
(P=0.03) from patients with CP as compared to 
healthy subjects. The values of NF-кB (P=0.67) 
were somewhat higher on GAgP PB leukocyte 
than in controls, but failed to reach the level of 
significance. The expression of NF-кB does not 
always result in high NF-кB activity. The tran-
scriptional activity of NF-кB was only inferred 
rather than demonstrated. Phosphorylation of 
DNA binding proteins is also important for DNA 
binding activity [18]. Earlier studies demon-
strated that the activation of NF-кB (p50/p65) 
is significant in periodontal diseased tissues 
[19]. Macrophages play a central role in the 
proinflammatory cytokine response induced by 
periodontopathogens and are an important tar-
get for lipopolysaccharide (LPS). Aggregatiba- 
cter actinomycetemcomitans LPS can activate 
the NF-кB pathway because it increases the 
expression and the phosphorylation states of 
the NF-кB p65 subunit by macrophages [20]. 
McDonald et al. [21] mentioned that the effect 
of LPS towards nuclear NF-кB activation in neu-
trophils was rapid and transient. In the absence 
of serum, a high concentration (100~500 ng/
ml) of LPS from Porphyromonas gingivalis and 
Escherichia coli enhanced the DNA binding 
activity of NF-кB [22]. These observations and 
our experiments suggest that a potent role of 
NF-кB in the transcriptional regulation of CCL2 
production in chronic periodontitis.
By the comprehensive microarray-based path-
way analysis (ingenuity pathway analysis, IPA), 
it has been demonstrated that CCL4 upregu-
lated CCL2 expression through CCL4/CCR5/c-
Jun and c-Fos/CCL2 pathway in collagen-
induced arthritis (CIA) rat and RA patients in an 
earlier study by the author [13]. In this study, 
the expressions of CCL4, CCR5, NF-кB gene 
and CCL2 protein were markedly up-regulated 
in both generalized aggressive and chronic 
periodontitis patients compared to the con-
trols, which paralleled the activation of NF-кB. 
However, the expression levels of NF-кB mRNA 
on PB leukocytes (P=0.67) were somewhat 
higher in the GAgP patients than in controls, no 
significant difference could also be observed in 
the CCR5 levels in the gingival tissue of CP 
(P=0.13) patients and healthy control. The sig-
nificant differences needs to be further investi-
gated in larger samples. These findings and our 
observations from a previous study [13, 14] 
suggest that CCL4 may stimulate CCL2 expres-
sion through CCL4/CCR5/NF-кB/CCL2 pathway 
on PB leukocytes of clinically CP patients. CCL4 
exerts its effects by binding to CCR5 on the sur-
face of the targeted leukocytes. CCR5, once 
activated, trigger a set of cellular signaling pro-
cesses that result in activation of phospholi-
pase C (PLC) together with inositol triphosphate 
(IP3) and dacylglyceerol (DAG) formation, intra-
cellular calcium release, protein kinase C (PKC) 
activation, and prolinerich tyrosine kinase 2 
(PYK2) activation. PYK2 regulates the activity 
of JNK and p38 in the MAPK pathway, leading 
to enhance the transactivation function of 
NF-кB. Expressions of CCL2 were markedly up-
regulated at the levels of protein, in parallel 
with the activation of NF-кB. Neither p38 nor 
c-Jun-N-terminal kinase (JNK) directly phos-
phorylates NF-кB [23]. However, inhibition of 
either pathway strongly reduces transcription 
from both NF-кB-dependent cytokine promot-
ers and promoters controlled by synthetic 
NF-кB binding sites [24]. p38 MAP kinase regu-
lates NF-кB-dependent transcription in part by 
TFIIB, and TATA-binding protein (TBP) [23]. The 
observation that NF-кB is able to interact 
directly with the TATA-binding protein of the 
TFIID complex, supports this possibility [25]. 
The MAP kinase p38 is involved in NF-кB-
dependent gene expression. This pathway is 
clearly dissected from IKK-induced NF-кB 
activation.
The AP-1 binding site is likely to be one of the 
important sites for CCL2 production [17]. AP-1 
activity is known to be regulated by MAPK path-
ways [26]. MAP kinase signaling pathways influ-
ence AP-1 activity by both increasing the abun-
dance of AP-1 components and by stimulating 
their activity directly [27]. The proinflammatory 
factors activate principal MAPK family mem-
bers, such as extracellular signal-regulated 
kinase (ERK), p38 MAPK and c-Jun N-terminal 
kinase (JNK), in responsive cell types [28]. The 
phosphorylation of MAPKs was shown to cause 
activation of their downstream transcription 
factors including Elk-1, c-Jun, ATF2 and CREB, 
which in turn regulated the expression of c-Fos 
and c-Jun, components of the AP-1 complex 
[29]. AP-1 can bind to AP-1-binding sites in pro-
moters and may activate the transcription of 
various target genes in response to cytokines 
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[27], while AP-1 functions are regulated through 
changes in the abundance of the Jun and Fos 
components as well as post-transcriptional 
modification by protein phosphorylation [30]. It 
has been shown that proinflammatory factors 
enhance c-Fos and c-Jun mRNA expression 
and/or AP-1-DNA binding activity in synovial 
fibroblasts, skin fibroblasts and gingival fibro-
blasts [31]. The activation of NF-кB, AP-1, or the 
combination of transcription factor NF-кB and 
AP-1 upregulates CCL2 gene transcriptions, 
depending on the types of cell or stimuli [32]. 
Taken together, these observations suggest 
that the p38 MAPK/NF-кB (in the present 
study), MAPKs/activator protein-1 (AP-1) and 
inhibitor of кB (IкB) kinases (IKKs)/IкB/nuclear 
factor-кB (NF-кB) cascades may mediate the 
CCL4 stimulated synthesis of CCL2 on CP PB 
leukocyte, though it has not been clarified 
whether these 3 pathways run on the same 
axis or in parallel. The p38MAPK cascade may 
act as the upstream signaling for the activation 
of AP-1 and NF-кB, which induce CCL2 expres-
sion. Based on the PCR and ELISA results show-
ing the significantly higher CCL4, CCR5, NF-кB 
mRNA levels and CCL2 protein level in CP PB, 
we deduced the signaling pathway (CCL4/
CCR5/PLC2/PKC/PYK2/p38 MAPK/NF-кB) of 
these cytokines in relation to CCL2 in this study.
In the present study, we identify higher serum 
levels of CCL2 in both generalized aggressive 
and chronic periodontitis patients compared to 
the controls. This points toward an increased 
systemic load of inflammatory mediators in 
patients with periodontitis. Heightened CCL2 
expression has been observed in several 
chronic inflammatory diseases such as athero-
sclerosis, osteoarthritis, rheumatoid arthritis, 
tumors and delayed type hypersensitivity reac-
tions [33]. Thus, any increase in plasma levels 
of CCL2 in patients with periodontitis who are 
otherwise clinically healthy may be hypothe-
sized to be a risk indicator for systemic illness-
es. Advances in diagnostic research are moving 
towards methods whereby the periodontal risk 
can be identified and quantified by objective 
measures using biomarkers. Patients with peri-
odontitis may have elevated circulating levels 
of specific inflammatory markers that can be 
correlated to the severity of the disease [34]. 
Estimation of serum CCL2 levels could be reli-
able indicators of periodontal disease activity. 
Further research in this direction could also 
reveal reliable markers to forecast the progres-
sion of periodontitis in high-risk groups.
In conclusion, we studied the possibility of a 
pathway involved in CCL2 expression in differ-
ent forms of human periodontal disease. We 
indicate that CCL4 increased CCL2 expression 
by binding to CCR5 and activating PKC (α, β), 
PYK2, and leading to MAPK (ERK, JUK and p38 
MAPK), which enhanced binding of TBP to the 
TATA box and TBP’s interaction with the p65 
subunit of NF-кB and resulted in CCL2 expres-
sion on CP PB leukocyte. To understand the 
precise signaling mechanism of CCL2 in human 
periodontitis, and to explain the cascade of 
events in chemokine-induced leukocyte migra-
tion into inflammatory sites, further study of 
animal models is indispensable. These findings 
may provide a better understanding of the 
mechanisms of periodontal pathogenesis. 
Targeting of CCL2 or its signaling pathways is a 
potentially novel therapeutic strategy for 
periodontitis.
Acknowledgements
We would like to acknowledge Jinbao Liu for his 
excellent technical assistance. This study was 
supported by grants from the Natural Science 
Foundation of Dental School of Tianjin Medical 
University (No. 2014YKY03).
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Lin Zhang, School 
of Dentistry, Hospital of Stomatology, Tianjin Medical 
University, 12 Qixiangtai Street, Heping District, 
Tianjin 300070, China. Tel: +86 22 23332007; Fax: 
+86 22 23332122; E-mail: linzhang@tmu.edu.cn
References
[1] Kinane DF, Lappin DF. Clinical pathological 
and immunological aspects of periodontal dis-
ease. Acta Odontol Scand 2001; 59: 154-160.
[2] Gemmell E, Carter CL, Seymour GJ. Chemo-
kines in human periodontal disease tissue. 
Clin Exp Immunol 2001; 125: 134-41.
[3] Sigusch B, Eick S, Pfister W, Klinger G, Glock-
man E. Altered chemotactic behavior of cre-
vicular PMNs in different forms of periodonti-
tis. J Clin Periodontol 2001; 28: 162-167.
[4] Kurtiş B, Tüter G, Serdar M, Akdemir P, Uygur 
C, Firatli E, Bal B. Gingival crevicular fluid levels 
CCL2 expression and its correlation with pathway
4409 Int J Clin Exp Pathol 2017;10(4):4400-4410
of monocyte chemoattractant protein-1 and 
tumor necrosis factor-alpha in patients with 
chronic and aggressive periodontitis. J Peri-
odontol 2005; 76: 1849-55. 
[5] Yu X, Antoniades HN, Graves DT. Expression of 
monocyte chemoattractant protein 1 in human 
inflamed gingival tissues. Infect Immun 1993; 
61: 4622-8.
[6] Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, 
Kelvin DJ. Preferential migration of activated 
CD4+ and CD8+ T cells in response to MIP-1 
alpha and MIP-1 beta. Science 1993; 260: 
355-8.
[7] Emingil G, Atilla G, Başkesen A, Berdeli A. Gin-
gival crevicular fluid EMAP-II, MIP-1alpha and 
MIP-1beta levels of patients with periodontal 
disease. J Clin Periodontol 2005; 32: 880-5.
[8] Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, 
Haines GK, Burdick MD, Pope RM, Strieter RM. 
Macrophage inflammatory protein-1 alpha. A 
novel chemotactic cytokine for macrophages 
in rheumatoid arthritis. J Clin Invest 1994; 93: 
921-8.
[9] Kawai T, Eisen-Lev R, Seki M, Eastcott JW, Wil-
son ME, Taubman MA. Requirement of B7 co-
stimulation for Th1-mediated inflammatory 
bone resorption in experimental periodontal 
disease. J Immunol 2000; 164: 2102-9.
[10] Repeke CE, Ferreira SB Jr, Claudino M, Silveira 
EM, de Assis GF, Avila-Campos MJ, Silva JS, 
Garlet GP. Evidences of the cooperative role of 
the chemokines CCL3, CCL4 and CCL5 and its 
receptors CCR1+ and CCR5+ in RANKL+ cell 
migration throughout experimental periodonti-
tis in mice. Bone 2010; 46: 1122-30. 
[11] Goebeler M, Gillitzer R, Kilian K, Utzel K, Bröck-
er EB, Rapp UR, Ludwig S. Multiple signaling 
pathways regulate NF-kappaB-dependent tran-
scription of the monocyte chemoattractant 
protein-1 gene in primary endothelial cells. 
Blood 2001; 97: 46-55.
[12] de Smit MJ, Brouwer E, Vissink A, van Winkel-
hoff AJ. Rheumatoid arthritis and periodontitis; 
a possible link via citrullination. Anaerobe 
2011; 17: 196-200. 
[13] Zhang L, Yu M, Deng J, Lv X, Liu J, Xiao Y, Yang 
W, Zhang Y, Li C. Chemokine signaling pathway 
involved in CCL2 expression in patients with 
rheumatoid arthritis. Yonsei Med J 2015; 56: 
1134-42.
[14] Zhang L, Zhao J, Kuboyama N, Abiko Y. ow-level 
laser irradiation treatment reduces CCL2 ex-
pression in rat rheumatoid synovia via a che-
mokinesignaling pathway. Lasers Med Sci 
2011; 26: 707-17.
[15] Armitage GC. Development of a classification 
system for periodontal diseases and condi-
tions. Ann Periodontol 1999; 4: 1-6.
[16] Baggiolini M, Dewald B, Moser B. Human che-
mokines: an update. Annu Rev Immunol 1997; 
15: 675-705.
[17] Kok SH, Hong CY, Kuo MY, Wang CC, Hou KL, 
Lin YT, Galson DL, Lin SK. Oncostatin M-in-
duced CCL2 transcription in osteoblastic cells 
is mediated by multiple levels of STAT-1 and 
STAT-3 signaling: an implication for the patho-
genesis of arthritis. Arthritis Rheum 2009; 60: 
1451-62.
[18] Asahara H, Fujisawa K, Kobata T, Hasunuma T, 
Maeda T, Asanuma M, Ogawa N, Inoue H, Sum-
ida T, Nishioka K. Direct evidence of high DNA 
binding activity of transcription factor AP-1 in 
rheumatoid arthritis synovium. Arthritis Rheum 
1997; 40: 912-8.
[19] Ambili R, Santhi WS, Janam P, Nandakumar K, 
Pillai MR. Expression of activated transcription 
factor nuclear factor-kappaB in periodontal-
lydiseased tissues. J Periodontol 2005; 76: 
1148-53.
[20] Bodet C, La VD, Gafner S, Bergeron C, Grenier 
D. A licorice extract reduces lipopolysaccha-
ride-induced proinflammatory cytokine secre-
tion by macrophages and whole blood. J Peri-
odontol 2008; 79: 1752-61. 
[21] McDonald PP, Bald A, Cassatella MA. Activa-
tion of the NF-kappaB pathway by inflammato-
ry stimuli in human neutrophils. Blood 1997; 
89: 3421-33.
[22] Sugita N, Kimura A, Matsuki Y, Yamamoto T, 
Yoshie H, Hara K. Activation of transcription 
Factors and IL-8 expression in neutrophils 
stimulated with lipopolysaccharide from Por-
phyromonas gingivalis. Inflammation 1998; 
22: 253-67.
[23] Carter AB, Knudtson KL, Monick MM, Hunning-
hake GW. The p38 mitogen-activated protein 
kinase is required for NF-kappaB-dependent 
gene expression. The role of TATA-binding pro-
tein (TBP). J Biol Chem 1999; 274: 30858-63.
[24] Vanden Berghe W, Plaisance S, Boone E, De 
Bosscher K, Schmitz ML, Fiers W, Haegeman 
G. p38 and extracellular signal-regulated ki-
nase mitogen-activated protein kinase path-
ways are required for nuclear factor-kappaB 
p65 transactivation mediated by tumor necro-
sis factor. J Biol Chem 1998; 273: 3285-90.
[25] Kerr LD, Ransone LJ, Wamsley P, Schmitt MJ, 
Boyer TG, Zhou Q, Berk AJ, Verma IM. Associa-
tion between proto-oncoprotein Rel and TATA-
binding protein mediates transcriptional acti-
vation by NF-kappa B. Nature 1993; 365: 
412-9.
[26] Whitmarsh AJ and Davis RJ. Transcription fac-
tor AP-1 regulation by mitogen-activated pro-
tein kinase signal transduction pathways. J 
Mol Med (Berl) 1996; 74: 589-607.
CCL2 expression and its correlation with pathway
4410 Int J Clin Exp Pathol 2017;10(4):4400-4410
[27] Karin M. The regulation of AP-1 activity by mito-
gen-activated protein kinases. J Biol Chem 
1995; 270: 16483-6.
[28] Matthews JS, O’Neill LA. Distinct roles for p42/
p44 and p38 mitogen-activated protein kinas-
es in the induction of IL-2 by IL-1. Cytokine 
1999; 11: 643-55.
[29] Minden A, Karin M. Regulation and function of 
the JNK subgroup of MAP kinases. Biochim 
Biophys Acta 1997; 1333: F85-F104.
[30] Minden A, Lin A, Smeal T, Derijard B, Cobb M, 
Davis R, Karin M. c-Jun N-terminal phosphory-
lation correlates with activation of the JNK sub-
group but not the ERK subgroup of mitogenac-
tivated protein kinases. Mol Cell Biol 1994; 14: 
6683-8.
[31] Reunanen N, Li SP, Ahonen M, Foschi M, Han J, 
Kahari VM. Activation of p38a MAPK enhan- 
ces collagenase-1 (matrix metalloproteinase 
(MMP)-1) and stromelysin-1 (MMP-3) expres-
sion by mRNA stabilization. J Biol Chem 2002; 
277: 32360-8.
[32] Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, 
Matsushima K, Kishimoto T, Akira S. Transcrip-
tion factors NF-IL-6 and NF-κB synergistically 
activate transcription of the inflammatory cyto-
kines interleukin 6 and interleukin 8. Proc Natl 
Acad Sci U S A 1993; 90: 10193-10197.
[33] Yu XH, Barnhill RL, Graves DT. Expression of 
monocyte chemoattractant protein-1 (MCP-1) 
in delayed type hypersensitivity reactions in 
the skin. Lab Invest 1994; 71: 235-66.
[34] de Queiroz AC, Taba M Jr, O’Connell PA, da Nó-
brega PB, Costa PP, Kawata VK, Trevisan GL, 
Novaes AB Jr, de Souza SL, Palioto DB, Grisi 
MF. Inflammation markers in healthy and peri-
odontitis patients: a preliminary data screen-
ing. Braz Dent J 2008; 19: 3-8.
